KR102763373B1 - 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포 - Google Patents

향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포 Download PDF

Info

Publication number
KR102763373B1
KR102763373B1 KR1020187002974A KR20187002974A KR102763373B1 KR 102763373 B1 KR102763373 B1 KR 102763373B1 KR 1020187002974 A KR1020187002974 A KR 1020187002974A KR 20187002974 A KR20187002974 A KR 20187002974A KR 102763373 B1 KR102763373 B1 KR 102763373B1
Authority
KR
South Korea
Prior art keywords
cells
bcg
dendritic cells
dendritic
dendritic cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187002974A
Other languages
English (en)
Korean (ko)
Other versions
KR20180022949A (ko
Inventor
마르닉스 엘. 보쉬
Original Assignee
노쓰웨스트 바이오써라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노쓰웨스트 바이오써라퓨틱스, 인크. filed Critical 노쓰웨스트 바이오써라퓨틱스, 인크.
Publication of KR20180022949A publication Critical patent/KR20180022949A/ko
Application granted granted Critical
Publication of KR102763373B1 publication Critical patent/KR102763373B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187002974A 2015-06-30 2016-06-29 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포 Active KR102763373B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187086P 2015-06-30 2015-06-30
US62/187,086 2015-06-30
PCT/US2016/040134 WO2017004230A1 (en) 2015-06-30 2016-06-29 Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

Publications (2)

Publication Number Publication Date
KR20180022949A KR20180022949A (ko) 2018-03-06
KR102763373B1 true KR102763373B1 (ko) 2025-02-07

Family

ID=57609106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002974A Active KR102763373B1 (ko) 2015-06-30 2016-06-29 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포

Country Status (14)

Country Link
US (2) US11124768B2 (https=)
EP (2) EP3317403B1 (https=)
JP (3) JP6985939B2 (https=)
KR (1) KR102763373B1 (https=)
CN (2) CN107849537A (https=)
AR (1) AR106496A1 (https=)
AU (2) AU2016286112B2 (https=)
CA (1) CA2990640A1 (https=)
ES (1) ES3032055T3 (https=)
IL (2) IL312668A (https=)
MX (2) MX2018000056A (https=)
PL (1) PL424035A1 (https=)
RU (1) RU2018103235A (https=)
WO (1) WO2017004230A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102919756B1 (ko) 2018-06-21 2026-01-28 유니버시테이트 젠트 치료용 수지상 세포의 시험관내 분화 및 성숙 방법

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
AU2020363707A1 (en) * 2019-10-07 2022-04-28 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法
CN119286782B (zh) * 2024-12-11 2025-04-04 上海赛笠百傲生物医药有限公司 一种高效诱导外周血来源单核细胞至不成熟树突状细胞的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273654A1 (en) * 2003-02-27 2013-10-17 Northwest Biotherapeutics, Inc. Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CN1636229B (zh) * 2001-09-06 2012-12-19 西北生物治疗药物公司 引发单核树突细胞和t细胞th-1应答的组合物和方法
WO2004000444A1 (en) 2002-06-19 2003-12-31 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for leukocyte enrichment
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
KR100887560B1 (ko) 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
EP3375868A1 (en) 2007-11-08 2018-09-19 Dana Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
AU2009237577B2 (en) 2008-04-18 2014-06-05 Baxter Healthcare Sa Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
EP2968406A4 (en) * 2013-03-14 2016-10-26 Icahn School Med Mount Sinai WITH AUTOLOGOUS TUMORLYSAT-LOADED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273654A1 (en) * 2003-02-27 2013-10-17 Northwest Biotherapeutics, Inc. Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102919756B1 (ko) 2018-06-21 2026-01-28 유니버시테이트 젠트 치료용 수지상 세포의 시험관내 분화 및 성숙 방법

Also Published As

Publication number Publication date
JP2022023248A (ja) 2022-02-07
CN114774356A (zh) 2022-07-22
MX2018000056A (es) 2018-05-28
BR112017028602A2 (pt) 2018-09-04
JP6985939B2 (ja) 2021-12-22
EP3317403A1 (en) 2018-05-09
RU2018103235A (ru) 2019-07-31
CN107849537A (zh) 2018-03-27
US20180187145A1 (en) 2018-07-05
CA2990640A1 (en) 2017-01-05
IL256522A (en) 2018-02-28
US11124768B2 (en) 2021-09-21
EP3317403A4 (en) 2019-07-03
JP2024101059A (ja) 2024-07-26
HK1255084A1 (en) 2019-08-02
AU2023202977A1 (en) 2023-06-01
US20220145246A1 (en) 2022-05-12
JP2018523996A (ja) 2018-08-30
AU2023202977B2 (en) 2026-03-05
WO2017004230A1 (en) 2017-01-05
AU2016286112A1 (en) 2018-02-15
KR20180022949A (ko) 2018-03-06
IL312668A (en) 2024-07-01
AU2016286112B2 (en) 2023-02-16
AR106496A1 (es) 2018-01-24
EP4574159A3 (en) 2025-09-17
IL256522B2 (en) 2024-10-01
EP3317403B1 (en) 2025-03-05
IL256522B1 (en) 2024-06-01
PL424035A1 (pl) 2019-01-02
ES3032055T3 (en) 2025-07-15
MX2023001622A (es) 2023-03-09
EP4574159A2 (en) 2025-06-25
RU2018103235A3 (https=) 2019-12-23

Similar Documents

Publication Publication Date Title
CN1738619B (zh) 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
AU2023202977B2 (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
JP2006510667A5 (https=)
JP2024019229A (ja) 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
HK40128538A (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
HK40077476A (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
AU2018260971B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK1255084B (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
BR112017028602B1 (pt) Método para produzir células dendríticas humanas isoladas parcialmente maduras e ativadas, e uso de uma composição farmacêutica compreendendo células dendríticas humanas parcialmente maduras e ativadas
AU2013234394A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240126

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241029

PG1601 Publication of registration